RESEARCH MONOGRAPH · KDC-MN-253

Hydroxyzine

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 2 min read

Our opinion on this compound

79/100

First-gen antihistamine that's quietly the best-tolerated anxiolytic nobody talks about

Hydroxyzine is the compound that always loses the marketing war and keeps winning on the science. Synthesized at UCB in 1956 by Morren, it's a first-generation piperazine antihistamine with H1 inverse agonism plus moderate affinity for 5-HT2A, alpha-1 adrenergic, and dopamine D2 receptors. That polypharmacology is exactly why it works for anxiety where pure antihistamines dont.

What we like is the human evidence. The Lader and Llopis trials in the 1990s and the more recent Llorca meta-analyses establish hydroxyzine as a real anxiolytic with effect sizes that hold up against benzodiazepines for GAD without the abuse profile or dependence liability. France has used it as a frontline anxiolytic for decades, which is a useful real-world signal that the rest of the world mostly ignored because the molecule is off-patent and unmarketable.

The mechanism for anxiety isnt fully reducible to H1 antagonism. Central histamine plays a more interesting role in arousal and anxiety than the first-gen labels suggest, and the 5-HT2A antagonism adds a piece that probably matters at the clinical doses used. The metabolite cetirizine retains the peripheral H1 activity without the central penetration, which is why the desensitization profile of hydroxyzine over time is more nuanced than people assume.

The QT prolongation signal is real and worth knowing. The FDA labeling change in 2015 wasnt overcautious; hERG affinity is documented and shows up at higher exposures. For research-use work this matters mostly as a known confound in cardiac safety pharmacology screens, where hydroxyzine is sometimes used as a positive control.

Sourcing is straightforward. Off-patent, multiple generics globally, pharmacopoeial. The two salts (hydrochloride and pamoate) have slightly different dissolution profiles but bioequivalent at relevant exposures.

Honestly the most interesting thing about hydroxyzine is what it tells you about how drug discovery economics shape what gets studied. A non-addictive anxiolytic with 70 years of safety data and modest but real efficacy should be a benchmark compound for new anxiolytic development, and it kind of is in academic settings, but the clinical literature is much thinner than it should be. Underrated as a research tool, especially for comparing newer anxiolytics against something that isnt a benzodiazepine or SSRI.

Evidence: 78
Mechanism: 72
Reliability: 78
Safety: 75
Sourcing: 90
Value: 88
Signal: 72
Staying power: 75

Plain-language summary Intrigue 56 / 100

Hydroxyzine (Atarax, Vistaril) is a first-generation antihistamine from UCB, approved in 1956, that crosses the blood-brain barrier readily and produces sedation and anxiolysis as a result. It is FDA-approved for anxiety and pruritus (itching), and unlike benzodiazepines it has no dependence or withdrawal potential, which makes it a useful first-line option for situational anxiety in patients with substance use histories. The trade-off is that the same antihistamine and anticholinergic effects produce dry mouth, constipation, urinary retention, and next-day grogginess. The active leftover after liver metabolism is cetirizine (Zyrtec), the over-the-counter allergy drug, which does not cross into the brain at clinical doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

First-generation H1 antihistamine anxiolytic

A first-generation piperazine H1 antihistamine with anxiolytic activity; the first non-controlled anxiolytic widely used in psychiatry.

Abstract

Hydroxyzine (2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; CAS 68-88-2; molecular formula C21H27ClN2O2; molecular weight 374.91) is a first-generation piperazine H1 antihistamine developed at UCB and approved by the FDA in 1956 under the trade names Atarax and Vistaril. Distinct from later antihistamines by clinically significant CNS penetration, producing the sedation and anxiolytic effects characteristic of first-generation H1 blockers. H1 affinity approximately 2 nM; secondary 5-HT2A antagonism (Ki approximately 10 nM) and weak D2 antagonism contribute to the anxiolytic profile. The principal active metabolite cetirizine retains H1 antagonism but loses CNS penetration owing to addition of a carboxylic acid group, and is marketed separately as a non-sedating antihistamine (Zyrtec). Plasma half-life is 14 to 25 hours; metabolism is hepatic. Approved for anxiety, pruritus, and as a preoperative sedative; off-label use in insomnia and as a benzodiazepine-sparing anxiolytic. Used as the canonical first-generation H1 antihistamine in mechanism studies.

Mechanism of action

First-generation H1 antagonism with CNS penetration; secondary 5-HT2A antagonism. Active metabolite cetirizine is non-CNS-penetrant.

Reported research dose ranges

Clinical 25 to 100 mg per oral administration daily, in divided doses. Rodent studies 5 to 30 mg/kg/day.

References

Schweizer E, et al. Hydroxyzine versus buspirone for anxiety. J Clin Psychiatry 1986.
Rickels K. Use of antianxiety agents in anxious outpatients. Psychopharmacology 1978.
Simons FE, et al. Cetirizine, the major metabolite of hydroxyzine. J Allergy Clin Immunol 1986.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-253 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Hydroxyzine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs